The lawsuit, Cheng v. Erasca, Inc., alleges that Erasca and its executives violated federal securities laws by failing to disclose material risks during the period between January 14, 2025, and April 26, 2026. Plaintiffs claim the company’s positive public statements regarding its pan-RAS molecular glue candidate, ERAS-0015, lacked a reasonable basis.

Central to the complaint are assertions that preclinical data for the drug relied on improper comparisons to Revolution Medicines, Inc. These comparisons allegedly exposed Erasca to significant risks concerning potential violations of patent and trade secret protections. Investors seeking to discuss their legal options or participate in the proceedings can contact Kahn Swick & Foti, LLC, or utilize the ClaimsFiler information service to manage their claims process.